The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
نویسندگان
چکیده
منابع مشابه
Incretin agents in type 2 diabetes.
OBJECTIVE To evaluate the emerging classes of antihyperglycemic agents that target the incretin pathway, including their therapeutic efficacy and side effect profiles, in order to help identify their place among the treatment options for patients with type 2 diabetes. QUALITY OF EVIDENCE MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews were searched. Most evidence is level I a...
متن کاملThe incretin axis in cardiovascular disease.
In 1964, studies in just 2 subjects offered a simple, salient, and fundamental observation reported in 612 words: Glucose induces a greater insulin response when introduced through the gastrointestinal tract than when injected intravenously (the Figure, A).2 This finding built on studies dating to 1928 that injecting extracts of small intestine into animals lowered their glucose levels. Subsequ...
متن کاملDo incretin-based therapies cause acute pancreatitis?
In 2007 a question was raised about the causal relationship between the first of the glucagon-like peptide 1 receptor agonists, exenatide, and pancreatitis, as postmarketing reports of pancreatitis in patients treated with this agent had been received by the Food and Drug Administration (FDA). There had been six reports of hemorrhagic pancreatitis, with two of the cases resulting in death. An u...
متن کاملThe potential of incretin-based therapies in type 1 diabetes.
Finding a cure for type 1 diabetes (T1D) has been elusive. Incretin-based therapies, since their approval, have demonstrated their clinical utilities in type 2 diabetes (T2D). Yet, their potential clinical benefits in T1D remain to be appraised. GLP-1, in addition to its insulinotropic action in alleviating hyperglycemia, possesses beneficial effects in protecting progressive impairment of panc...
متن کاملIncretin-based Therapy in the Management of Type 2 Diabetes
Type 2 diabetes is a progressive disease due to reduced beta cell mass, which results in the failure of traditional treatment and the need for more intensive therapeutical measures to maintain a good glycaemic control. Within the last decade there was a preoccupation for developing new classes of drugs to achieve several goals: glycaemic control, weight loss and to preserve residual beta cell m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Nephrology
سال: 2014
ISSN: 1759-5061,1759-507X
DOI: 10.1038/nrneph.2014.90